Arthritis news. Anytime. Anywhere.

Fibromyalgia: Myths, Facts, and Future Hopes

Woman with hand on faceThe Canadian Institute for the Relief of Pain and Disability (CIRPD) will be conducting a webinar tomorrow (April 16) at 11:00am PDT/2:00pm EDT on fibromyalgia. The webinar will feature Connie Leudtke, MA, RN-BC, Assistant Professor at Mayo Clinic College of Medicine and Nursing Supervisor at the Mayo Clinic Pain Rehabilitation Center and Mayo Fibromyalgia and Chronic Fatigue Clinic. Drawing from 25 years of experience, Leudtke will dispel some common myths about fibromyalgia. She will also provide up-to-date information on diagnosis and treatment.

At the end of the webinar, attendees will be able to:  Continue reading

Arthritis Consumer Experts (ACE) at the 2014 CADTH Symposium

Snow over QuebecCheryl Koehn, President of Arthritis Consumer Experts (ACE), spoke in today’s session at the 2014 CADTH Symposium held at the Hilton Lac-Leamy, Gaitneu, Quebec. The 2014 CADTH Symposium is the tenth pan-Canadian forum organized by the Canadian Agency for Drugs and Technologies in Health for producers and users of evidenced-based information on drugs and other health technologies in Canada. This year’s Symposium is titled The Realities of Health Care Decision-Making: Evidence, Values, and Collaboration and comprises of 3 plenary sessions, 22 panel discussions, 9 oral sessions, 13 workshops and more than 40 scientific posters – all helping to enhance decision-making, reduce uncertainty, improve health outcomes and increase the value and sustainability of health care in Canada and around the world.

ACE is proud to be a part of the Symposium. Cheryl was one of the panellists today at “Session D2 – Panel Discussion: Health Technology Assessment of Biosimiliars (Subsequent Entry Biologics): A Canadian Perspective.” She spoke alongside the following panellists: Continue reading

Updates to Non-Insured Health Benefits Program for rheumatoid arthritis

Totem PoleThe Canadian Rheumatology Association (CRA) has announced that effective March 10, 2014, the Non-Insured Health Benefits (NIHB) Program’s limited use criteria for coverage of biologic therapies for rheumatoid arthritis (RA) has been modified. The change came following a recommendation from the NIHB Drugs and Therapeutics Advisory Committee. As a result, there are changes to the following biologics for RA: infliximab (Remicade®), etanercept (Enbrel®), adalimumab (Humira®), golimumab (Simponi®), abatacept (Orencia®) and certolizumab (Cimzia®).

How does the biologics reimbursement in your province and territory’s provincial formulary compare to the NIHB’s coverage? Find out by reading the JointHealth™ report card.

Below is an excerpt from the CRA on the changes: Continue reading

Save the date for Otto Kamensek’s “Shard’s, Bone Deep” art exhibit!

Picture of Otto Kamensek

Photo from the Port Moody Arts Centre

From April 17-May 8, the Port Moody Arts Centre will feature the clay sculptures of Otto Kamensek, a person living with juvenile idiopathic arthritis.

The Port Moody Arts Centre will be featuring the clay sculptures of Otto Kamensek in an exhibit called Shard’s, Bone Deep from April 17-May 8. The exhibit will be running concurrently with the visual art exhibit of Maggie White’s Seeing Red, Feeling the Blues and Rocking It.

Kamensek has been the ceramic artist-in-residence at the Port Moody Arts Centre since last May. He is an accomplished ceramic artist, a community volunteer and member of the Patient Advisory Board of the Arthritis Research Centre of Canada. His artwork reflects his own health challenges with juvenile idiopathic arthritis and how it has affected his body and the world around him.

Kamensek will be presenting a talk titled “Art & Arthritis with Otto Kamensek” on Thursday, May 1 from 7-9pm. In his talk, he will discuss the release of pain, frustration and stress through art. Guests at the talk will be able to join Kamensek on a tour of his studio and exhibition at the Port Moody Arts Centre. The suggested donation for the talk is $10; all proceeds will go to the ‘OK Bursary’, a program set up to assist artists in financial need. To reserve your seat, please call the venue at 604-931-2008.

Do not miss this opportunity to support a friend and fellow member of your arthritis community! We welcome you to share your experience at the exhibit with us in the comments section below. Tell us what your favourite piece is and why.

Better Pharmacare Coalition meeting with BC Liberal Caucus

Cheryl Koehn PresentationCheryl Koehn, the Founder and President of the Arthritis Consumer Experts, presented at the Better Pharmacare Coalition meeting with the BC Liberal caucus today in Victoria. The Arthritis Consumer Experts is a member of the Better Pharmacare Coalition – an organization that works on behalf of its members to ensure appropriate and timely BC PharmaCare program coverage for evidence-based prescription medications and health products.

We want to remind you that you, too, can take action and arrange for a meeting with your government leaders. Challenge the misperceptions of arthritis. Speak up. Tell your story. Change arthritis. Continue reading

Call for patient input on treatment for psoriatic arthritis

Megaphone GraphicDo you have psoriatic arthritis or care for someone who does? We want your valuable input.

On January 21 of this year, Health Canada approved ustekinumab for the treatment of psoriatic arthritis. Now, the Common Drug Review (CDR) is welcoming input on the manufacturer’s submission of ustekinumab (Stelara®) for the treatment of psoriatic arthritis (PsA) from patients and their caregivers.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient groups, like Arthritis Consumer Experts (ACE). We would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading